Immatics Announces Full Year 2023 Financial Results and Corporate Update [Yahoo! Finance]
Immatics N.V. - Ordinary Shares (IMTX)
Company Research
Source: Yahoo! Finance
median duration of response not reached at median follow-up of 14.4 months; IMA203 was well tolerated Registration-enabling randomized Phase 2/3 trial for ACTengine® IMA203 GEN1 in 2L+ melanoma planned to begin in 2024 Next data update on IMA203 GEN1 and IMA203CD8 GEN2 planned for 2H 2024 First clinical data updates for Immatics' next-generation TCR Bispecifics, TCER® IMA401 (MAGEA4/8) and TCER® IMA402 (PRAME), from ongoing Phase 1 dose escalation trials planned for 2H 2024; updates to include details on safety, pharmacokinetics and initial anti-tumor activity In May 2023, Bristol Myers Squibb exercised first opt-in into the autologous cell therapy collaboration ($15 million option fee received) and made a $35 million equity investment in July 2023 In September 2023, Immatics and Moderna announced a strategic multi-platform collaboration to develop innovative oncology therapeutics; Immatics received $120 million upfront payment, and the total deal volume could exceed $1.7 bi
Show less
Read more
Impact Snapshot
Event Time:
IMTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMTX alerts
High impacting Immatics N.V. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
IMTX
News
- Immatics Announces Full Year 2023 Financial Results and Corporate UpdateGlobeNewswire
- With 52% institutional ownership, Immatics N.V. (NASDAQ:IMTX) is a favorite amongst the big guns [Yahoo! Finance]Yahoo! Finance
- Immatics' (NASDAQ:IMTX) investors will be pleased with their notable 35% return over the last year [Yahoo! Finance]Yahoo! Finance
IMTX
Earnings
- 11/14/23 - Beat
IMTX
Sec Filings
- 3/21/24 - Form 6-K
- 3/21/24 - Form 20-F
- 2/14/24 - Form SC
- IMTX's page on the SEC website